Success with new treatment for Parkinson’s

Phase II trials of liquid levodopa/carbidopa (LD/CD) (ND0612L) by Israeli biotech NeuroDerm have shown improvements in patients with moderate to severe Parkinson’s disease.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *